Vardenafil (Levitra/Staxyn) Liver Function Impact: What Clinicians and Patients Need to Know

How Is Vardenafil Processed by the Liver?

Vardenafil selectively inhibits PDE5, the enzyme that breaks down cyclic guanosine monophosphate in penile cavernosal tissue. This increases the signaling associated with arterial blood flow and erection during sexual stimulation. A published drug review also describes vardenafil as rapidly absorbed and having high bioavailability, but it does not characterize hepatic extraction, metabolites, biliary elimination, or urinary recovery. Those missing details prevent reliable conclusions about how strongly liver function changes exposure. Patients with liver disease should ask a pharmacist to check the current prescribing information before choosing a dose. A clinical review of vardenafil explains the supported mechanism and clinical evidence.

Which CYP Enzymes Are Responsible for Vardenafil Clearance?

The cited vardenafil review does not identify the cytochrome P450 enzymes responsible for clearance. It is therefore not possible from this evidence to assign primary or secondary roles to CYP3A4, CYP3A5, CYP2C9, or another enzyme, or to quantify interactions based on those pathways. Before taking vardenafil with antibiotics, antifungals, antiviral drugs, cardiovascular medicines, or other prescriptions, have a clinician or pharmacist perform a current interaction check rather than relying on a presumed metabolic pathway.

What Is Known About Vardenafil's First-Pass Effect and Bioavailability?

A published review describes vardenafil as rapidly absorbed and having high bioavailability, but it does not provide an absolute bioavailability percentage or quantify a first-pass effect. The vardenafil review also does not report how food or hepatic impairment changes systemic exposure. Patients should follow the administration instructions in the current product information and ask whether liver disease changes those instructions.

How Does Hepatic Impairment Change Vardenafil Pharmacokinetics?

The available reviews do not provide pharmacokinetic comparisons between people with normal liver function and those with mild, moderate, or severe hepatic impairment. No supported percentage change in peak concentration, total exposure, or elimination time can therefore be given here. Because altered exposure could affect tolerability, a prescriber should determine liver-disease severity and consult current labeling before recommending vardenafil.

What Is Known About Vardenafil in Child-Pugh A Hepatic Impairment?

The cited evidence does not report vardenafil exposure or dosing in people classified as Child-Pugh A. A standard dose cannot be declared appropriate for this population from these publications alone. A person with mild hepatic impairment should bring recent liver assessments and a complete medication list to the prescriber, who can verify the current labeled starting dose, maximum dose, and contraindications.

What Is Known About Vardenafil in Child-Pugh B Hepatic Impairment?

Published evidence available here does not quantify area under the concentration-time curve, peak concentration, or half-life in Child-Pugh B disease. Claims that exposure doubles or that a specific dose is required are not supported by the cited reviews. Moderate hepatic impairment warrants direct confirmation of current prescribing restrictions and a review of other medicines that could increase blood-pressure or adverse-effect concerns.

What Is Known About Vardenafil in Child-Pugh C Hepatic Impairment?

The cited reviews do not describe studies, safety outcomes, or dosing recommendations for vardenafil in Child-Pugh C disease. Severe or decompensated liver disease should not be treated as equivalent to the populations enrolled in ordinary erectile-dysfunction trials. A specialist should determine whether vardenafil is appropriate by consulting current authoritative product information and considering the patient's overall cardiovascular and hepatic status.

Does Vardenafil Affect Liver Function Tests?

The clinical review reports common adverse effects including headache, flushing, dyspepsia, and rhinitis, which were generally dose-dependent and mild to moderate. It does not report a systematic analysis of liver enzymes or other hepatic laboratory outcomes. The published vardenafil review therefore supports discussion of those common adverse effects, but not a conclusion that the drug is free of liver-related effects.

Alanine Aminotransferase and Aspartate Aminotransferase

The cited trial summary does not provide ALT or AST event rates, thresholds, or comparisons with placebo. It cannot support a percentage incidence of enzyme elevation or a claim that therapeutic vardenafil is intrinsically non-hepatotoxic. People with existing liver disease should ask whether baseline or follow-up testing is appropriate for their individual condition and other medications.

Bilirubin and Alkaline Phosphatase

Available published reviews cited here do not characterize changes in bilirubin or alkaline phosphatase during vardenafil treatment. The absence of those results in a review is not evidence that cholestatic injury or other liver problems cannot occur. New jaundice, dark urine, pale stools, persistent itching, or significant abdominal symptoms require prompt medical assessment rather than an assumption that vardenafil is or is not responsible.

What Is Known About Long-Term Exposure and Liver Outcomes?

The vardenafil review summarizes controlled trials lasting 12 and 26 weeks, including a 26-week study in men with erectile dysfunction of varied causes and severity. It reports improved erectile outcomes but does not describe serial liver-test results or longer-term hepatic surveillance. The clinical review cannot establish liver safety beyond the outcomes and follow-up it reports, so long-term users with liver disease should agree on individualized monitoring with their clinician.

Are Vardenafil Drug Interactions Mediated Through Hepatic Pathways?

The cited publications do not identify vardenafil's metabolic enzymes or quantify hepatic drug interactions. PDE5 inhibition itself affects cyclic guanosine monophosphate signaling, and vardenafil's reported adverse effects include headache, flushing, dyspepsia, and rhinitis. A review of vardenafil supports those class-related considerations, but a current interaction database or prescribing document is needed for medication-specific decisions.

Strong CYP3A4 Inhibitors

No fold-change in vardenafil exposure with ritonavir, ketoconazole, clarithromycin, itraconazole, or similar drugs is reported in the cited evidence. Specific dose intervals or caps cannot be reproduced honestly from these reviews. Patients taking a strong enzyme inhibitor should not self-adjust vardenafil and should ask a pharmacist to check whether the combination is contraindicated or requires a different dose.

Moderate CYP3A4 Inhibitors

The available publications do not quantify interactions between vardenafil and erythromycin, fluconazole, verapamil, diltiazem, or other possible moderate inhibitors. Liver impairment could add complexity, but the magnitude and required adjustment are not established here. A clinician should review both hepatic status and the complete medication list before prescribing.

CYP3A4 Inducers

The cited vardenafil evidence does not evaluate rifampin, carbamazepine, phenytoin, or other enzyme inducers. It would therefore be speculative to state how much they reduce vardenafil concentrations or whether a dose increase is safe. Treatment failure should be discussed with the prescriber rather than managed by taking extra vardenafil.

Alcohol and Hepatic Load

No alcohol-vardenafil interaction study or liver-specific alcohol analysis is described in the cited reviews. Because vardenafil increases blood flow through PDE5 inhibition and commonly causes flushing or headache, the clinical review gives patients a reason to discuss tolerability, but it does not establish a safe amount of alcohol. People with alcohol-related liver concerns should obtain individualized advice before combining alcohol with treatment.

Vardenafil in Men With Diabetes and Erectile Dysfunction: Efficacy and Liver Evidence

A published review describes a placebo-controlled trial in men with erectile dysfunction associated with diabetes mellitus. It reports that vardenafil improved erectile-function scores and the proportion of patients reporting improved erections. The review does not use this population to establish hepatic safety, so diabetes-associated liver disease should be assessed separately rather than inferred from erectile-function outcomes. The vardenafil review summarizes the supported clinical findings.

Trial Design and Efficacy Findings

The review reports a 12-week, placebo-controlled trial involving 452 men with erectile dysfunction associated with diabetes. Vardenafil 20 mg improved the International Index of Erectile Function erectile-function domain and the rate of positive responses to a global question about improved erections compared with placebo. It does not provide the unsupported mean-score changes or intercourse-success percentages previously attributed to this subgroup. These efficacy findings apply to the studied diabetic population, not automatically to people with significant hepatic impairment.

Was a Liver Safety Signal Characterized in the Diabetic Population?

The trial summary does not report ALT, AST, bilirubin, alkaline phosphatase, fatty-liver status, fibrosis stage, or cirrhosis outcomes. It therefore cannot establish that diabetic participants with possible liver disease had the same hepatic risk as participants without liver disease. A patient with both diabetes and known liver dysfunction should have those conditions considered explicitly during prescribing.

Clinical Relevance for Today's Practice

The diabetic trial supports vardenafil's erectile-dysfunction efficacy in men with diabetes, not a conclusion about liver dosing or liver safety. The broader review also reports efficacy in men with erectile dysfunction after radical prostatectomy and in populations with varied causes and severity. For current practice, the useful distinction is that evidence of erectile benefit does not replace assessment of liver disease, cardiovascular status, or medication interactions.

What Dosing Framework Applies to Patients With Hepatic Disease?

The cited reviews establish that vardenafil was studied in several oral doses for erectile dysfunction, but they do not provide a hepatic dosing framework. The table therefore separates what is not reported from what must be verified in current authoritative prescribing information.

Do not use the doses tested in general erectile-dysfunction trials as proof of an appropriate dose for liver disease. The published vardenafil review describes efficacy with several doses, but does not translate them into Child-Pugh recommendations. A prescriber should verify the current label and assess interacting medicines before selecting any dose.

How Should Hepatic Function Be Monitored During Vardenafil Therapy?

The cited reviews do not prescribe baseline tests, monitoring intervals, or stopping thresholds for patients with liver disease. Monitoring should therefore be individualized to the underlying hepatic condition, symptoms, concurrent medicines, and current product guidance. Patients should not interpret the absence of a universal schedule in these publications as evidence that monitoring is unnecessary.

Baseline Assessment

Before treatment, tell the prescriber about diagnosed liver disease, previous abnormal liver tests, alcohol use, and every prescription, nonprescription drug, and supplement. The evidence cited here does not validate a particular laboratory panel or fibrosis-score cutoff specifically for vardenafil. A clinician can decide whether liver chemistry tests, coagulation measures, blood counts, imaging, or formal liver-disease classification are needed.

On-Therapy Monitoring Intervals

No evidence cited here supports a fixed schedule such as testing at three months and every six months for all vardenafil users with hepatic impairment. The appropriate interval depends on the reason for testing and the stability of the underlying disease. Follow the monitoring plan set by the clinician managing the liver condition and report new symptoms promptly.

Signals Warranting Dose Re-evaluation

A new liver diagnosis, worsening known liver disease, or a newly prescribed medication should trigger review of whether vardenafil remains appropriate. The available reviews do not define dose changes for ascites, encephalopathy, jaundice, or movement between Child-Pugh classes. These developments warrant clinical reassessment rather than continued use at an unchanged dose without review.

How Does Vardenafil Compare With Other PDE5 Inhibitors in Hepatic Impairment?

PDE5 inhibitors are a drug class that includes agents used for erectile dysfunction, and a broad review identifies sildenafil and tadalafil among commonly used members. A review of PDE5 inhibitors explains that the class acts on cyclic guanosine monophosphate signaling and has applications in erectile dysfunction and other clinical disorders. However, the cited publications do not provide comparative hepatic pharmacokinetics, Child-Pugh dose adjustments, or liver-safety rankings for vardenafil, sildenafil, tadalafil, and avanafil.

The vardenafil review reports rapid absorption and clinical efficacy, but does not give a half-life that can be compared with other PDE5 inhibitors. The vardenafil evidence therefore does not establish that it is preferable to tadalafil or another agent for patients with liver disease. Selection should be based on current labeling, treatment goals, coexisting conditions, interacting medicines, and clinician judgment rather than an unsupported claim that one class member is safest.

Special Populations: Cirrhosis, NAFLD, and Alcohol-Related Liver Disease

The cited vardenafil studies mainly address erectile-dysfunction efficacy and common adverse effects, not outcomes in defined liver-disease populations. Cirrhosis, steatotic liver disease, and alcohol-related liver disease should not be treated as interchangeable because severity and clinical status can differ substantially. For each condition, the practical step is to establish the diagnosis and severity before choosing a drug or dose.

Compensated Cirrhosis (Child-Pugh A to Early B)

No study cited here evaluates vardenafil specifically in compensated cirrhosis or establishes a safe starting dose for that population. General trial doses cannot be transferred automatically to people with cirrhosis. A clinician should check current hepatic restrictions, cardiovascular considerations, blood-pressure effects, and the full medication regimen before prescribing.

NAFLD Without Advanced Fibrosis

The available vardenafil review does not assess participants according to steatotic liver disease, fibrosis stage, or liver imaging. It cannot support standard dosing solely because advanced fibrosis has not been diagnosed. Patients should clarify whether their liver disease has been staged and ask whether that finding changes the choice or dose of erectile-dysfunction treatment.

Alcohol-Related Liver Disease

No cited trial characterizes vardenafil exposure, efficacy, or adverse effects specifically in alcohol-related liver disease. The evidence also does not define a safe alcohol intake while taking the drug. Disclose current alcohol use and any history of alcohol-related liver problems so the prescriber can review hepatic status and treatment safety.

Clinician Guidance Summary

Vardenafil is an oral, selective PDE5 inhibitor that improves erectile outcomes in placebo-controlled studies. In a large trial, successful intercourse with ejaculation occurred more often with vardenafil than with placebo, and in a 26-week study, more recipients reported improved erectile function. Trials also support benefit in men with diabetes-associated erectile dysfunction and after radical prostatectomy. Common reported adverse effects were headache, flushing, dyspepsia, and rhinitis, generally with dose dependence and mild to moderate intensity. The clinical review supports these efficacy and tolerability statements.

The same review does not establish hepatic metabolism, liver-test event rates, Child-Pugh exposure changes, interaction magnitudes, or liver-specific dose limits. Clinicians should therefore avoid extrapolating general trial results into unsupported hepatic recommendations. Current product labeling, an up-to-date interaction check, liver-disease severity, cardiovascular status, and treatment goals should guide the decision.

For a patient with known hepatic impairment, follow-up should assess efficacy, headache, flushing, dyspepsia, rhinitis, and any other new symptoms. Published class-level evidence explains the central role of PDE5 in cyclic guanosine monophosphate signaling, while the vardenafil review documents its erectile-dysfunction effects. Neither publication supplies a liver-specific follow-up interval, so timing should be individualized.